Superdrugs vs Superbugs

Reducing the burden of infectious diseases by applying multidisciplinary and collaborative research to craft innovative, translational solutions.

 

Our group is focused on applying medicinal chemistry to the discovery of translational solutions to antimicrobial resistance.

We work on developing new antibiotics, novel non-antibiotic therapies, diagnostics, and basic research tools to help understand the interactions between antibiotics and resistant bacteria.

While our emphasis is on bacterial infections, we are also exploring solutions to fungal, parasitic and viral diseases.

Group videos

Interviews of AMR

CO-ADD

Group leader

Dr Mark Blaskovich

Associate Professor Mark Blaskovich

Group Leader, Superdrugs vs Superbugs

Director, IMB Centre for Superbug Solutions

  +61 7 334 62994
  m.blaskovich@imb.uq.edu.au
  UQ Researcher Profile

Our approach

Our research is anchored in medicinal chemistry, which is at the core of all our research themes. I believe strongly in the strength of multidisciplinary and collaborative research, leveraging the expertise of national and international investigators in a wide range of fields to jointly develop solutions to the urgent threat of antimicrobial resistance. We are focused on developing translational outcomes, with real-world impact.

Aims to achieve

Our vision is to reduce the burden of infectious diseases by applying multidisciplinary and collaborative research to craft innovative, translational solutions.

Research areas
 


New Antibiotics

  • Anti-bacterial, anti-fungal, and anti-parasitic projects
  • High throughput screening
  • medicinal and synthetic chemistry 
  • machine learning and chemoinformatics approaches
  • peptidomimetic drug design
  • microbiological characterisation
  • mode of action studies
  • drug formulation
     


Non-Antibiotic Alternatives

  • potentiators
  • antibody-drug conjugates
  • immune-stimulating therapies
  • virulence factors
  • lysins





     


Antimicrobial Diagnostics

  • antibiotic-derived fluorescent probes for fundamental investigations into bacterial resistance
  • flow cytometry characterisation of bacteria
  • imaging diagnostics: fluorescent 'bacteria paint', PET and SPECT radiolabeled agents, magnetic particle imaging
  • derivatised nanoparticles for bacterial capture and detection

Our Team

Group Leader

Researchers

Administrative Assistant

  • Miss Veah Tapat

    Research Administration Officer
    Institute for Molecular Bioscience

Research excellence

$1.3 billion+ commercial investment attracted to IMB research
1454 international collaborators
 
385 original publications in 2020
 
$28M in research funding last calendar year
 
20%+ of patent families at UQ are derived from IMB research
100% of donations go to the cause
 

Help us shape the future
 

 Donate        Study with us

Stories

Pages

Connect with us

           ​